Neurotrophic and antioxidant potential of neuropeptides and trace elements
https://doi.org/10.14412/2074-2711-2015-4-92-100
Abstract
Neurotrophic therapy with brain extract-based drugs has been performed for decades. The basis for their neurotrophic activity is amino acids and neuropeptides. However, incomplete information on the composition of these drugs precludes a detailed description of mechanisms through which their pharmacological effects occur. The review considers the results of the most recent molecular pharmacological investigations and the mechanisms of therapeutic action of cerebrolysin.
About the Authors
O. A. Gromova
Ivanovo State Medical Academy, Ministry of Health of Russia;
Russian Satellite Center of Trace Element Institute for UNESCO, N.I. Pirogov Russian National Medical Research University, Ministry of Health of Russia
Russian Federation
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000;
1, Ostrovityanov St., Moscow 117997
A. V. Pronin
Ivanovo State Medical Academy, Ministry of Health of Russia
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000
I. Yu. Torshin
Russian Satellite Center of Trace Element Institute for UNESCO, N.I. Pirogov Russian National Medical Research University, Ministry of Health of Russia;
Moscow Institute of Physics and Technology
Russian Federation
Russian Federation
1, Ostrovityanov St., Moscow 117997;
9, Institutskiy Lane, Dolgoprudnyi, Moscow Region 141700
A. G. Kalacheva
Ivanovo State Medical Academy, Ministry of Health of Russia
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000
T. R. Grishina
Ivanovo State Medical Academy, Ministry of Health of Russia
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000
Russian Federation
8, Sheremetevsky Passage., Ivanovo 153000
References
1. Гусев ЕИ, Скворцова ВИ, Стаховская ЛВ. Эпидемиология инсульта в России. Consilium Medicum. 2003;(5):12-8. [Gusev EI, Skvortsova VI, Stakhovskaya LV. Epidemiology of stroke in Russia. Consilium Medicum. 2003;(5):12-8. (In Russ.)].
2. Парфенов ВА, Вербицкая СВ. Факторы риска и профилактика инсульта при фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2014;6(3):55-60. [Parfenov VA, Verbitskaya SV. The risk factors and prevention of stroke in atrial fibrillation. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2014;6(3):55-60. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2014-3-55-60
3. Гомазков ОА. Старение мозга и нейротрофическая терапия. Москва: ИКАР; 2011. С. 41-68. [Gomazkov OA. Starenie mozga i neirotroficheskaya terapiya [The aging of brain and neurotrophic therapy]. Moscow: IKAR; 2011. P. 41-68.]
4. Calissanto P, Matrone C, Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer’s disease. Dev Neurobiol. 2010 Apr;70(5):372-83. doi: 10.1002/dneu.20759.
5. Matrone C, Barbagallo AP, La Rosa LR, et al. APP is phosphorylated by TrkA and regulates NGF/TrkA signaling. J Neurosci. 2011 Aug 17;31(33):11756-61. doi: 10.1523/JNEUROSCI.1960-11.2011.
6. Allard S, Leon WC, Pakavathkumar P, et al. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci. 2012 Feb 8;32(6):2002-12. doi: 10.1523/JNEUROSCI.1144-11.2012.
7. Kemp SW, Webb AA, Dhaliwal S, et al. Dose and duration of nerve growth factor (NGF) administration determine the extent of behavioral recovery following peripheral nerve injury in rats. Exp Neurol. 2011 Jun;229(2):460-70. doi: 10.1016/j.expneurol.2011.03.017.
8. Epub 2011 Mar 31.
9. Ubhi K, Rockenstein E, Vazquez-Roque R, et al. Cerebrolisin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res. 2013 Feb;91(2):167-77. doi: 10.1002/jnr.23142. Epub 2012 Nov 14.
10. Степаничев МЮ. Современные подходы и перспективы применения генной терапии болезни Альцгеймера. Нейрохимия. 2011;28(3):181-91. [Stepanichev MYu. Modern approaches and prospects of application for gene therapy of Alzheimer's disease. Neirokhimiya. 2011;28(3):181-91. (In Russ.)].
11. Scott SA, Crutcher KA. Nerve growth factor and Alzheimer's disease. Rev Neurosci. 1994 Jul-Sep;5(3):179-211.
12. Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012 Nov 29;10:239. doi: 10.1186/1479-5876-10-239.
13. Jiang Y, Wei N, Lu T, et al. Intranasalbrainderived neurotrophic factor protect brainfrom ischemic insult via modulating local inflammation in rats. Neuroscience. 2011 Jan 13;172:398-405. doi: 10.1016/j.neuroscience.2010.10.054. Epub 2010 Oct 27.
14. Rybakowcki J, Borkovska A, Czerski P, et al. Polimorphism of the brain-derived neurotrophic factor gene and performance on a cognitive test in bipolar patients. Bipolar Disord. 2003 Dec;5(6):468-72.
15. Yamagishi S, Matsumoto T, Yokomaku D, et al. Comparison of inhibitory effects of brainderived neurotrophic factor and insulin-like growth factor on low potassium-induced apoptosis and activation of p38 MAPK and c-Jun in cultured cerebellar granule neurons. Brain Res Mol Brain Res. 2003 Nov 26;119(2):184-91.
16. Торшин ИЮ, Громова ОА. Мультимодальный эффект Церебролизина против воинствующего редукционизма. Неврологический вестник. Журнал имени В.М. Бехтерева. 2008;XL(3):83-91. [Torshin IYu, Gromova OA. Multimodal effects of Cerebrolysin against militant reductionism. Nevrologicheskii vestnik. Zhurnal imeni V.M. Bekhtereva. 2008;XL(3):83-91. (In Russ.)].
17. Громова ОА, Третьяков ВЕ, Мошковский СА и др. Олигопептидная мембранная фракция церебролизина. Журнал неврологии и психиатрии им. C.C. Корсакова. 2006;106(7):68-70. [Gromova OA, Tret'yakov VE, Moshkovskii SA, et al. Oligopeptide membrane fraction of Cerebrolysin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2006;106(7):68-70. (In Russ.)].
18. Громова ОА, Красных ЛМ, Гусев ЕИ, Никонов АА. Витаминная активность церебролизина. Журнал неврологии и психиатрии им. C.C. Корсакова. 2005;105(5):59-61. [Gromova OA, Krasnykh LM, Gusev EI, Nikonov AA. Vitamin activity of Cerebrolysin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;105(5):59-61. (In Russ.)].
19. Громова ОА, Торшин ИЮ, Гусев ЕИ и др. Молекулярные механизмы воздействия аминокислот в составе Церебролизина на нейротрансмиссию. Нейротрофические и нейропротективные эффекты аминокислот. Трудный пациент. 2010;8(4):25-31. [Gromova OA, Torshin IYu, Gusev EI, et al. Molecular mechanisms of action of amino acids in the composition of Cerebrolysin on neurotransmission. Neurotrophic and neuroprotective effects of amino acids. Trudnyi patsient. 2010;8(4):25-31. (In Russ.)].
20. Торшин ИЮ, Громова ОА, Тогузов РТ, Волков АЮ. Элементный состав нейропротекторов природного происхождения. Новости медицины и фармации. 2010; (316). [Torshin IYu, Gromova OA, Toguzov RT, Volkov AYu. The elemental composition of the natural neuroprotective agents. Novosti meditsiny i farmatsii. 2010;(316). (In Russ.)].
21. Громова ОА, Кудрин АВ, Катаев СИ и др. Влияние церебролизина на микроэлементный гомеостаз головного мозга. Журнал неврологии и психиатрии им. C.C. Корсакова. 2003;(11):34-8. [Gromova OA, Kudrin AV, Kataev SI, et al. The influence of Cerebrolysin on trace element homeostasis of the brain. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2003;(11):34-8. (In Russ.)].
22. Торшин ИЮ, Громова ОА. Экспертный анализ данных в молекулярной фармакологии. Москва: МЦНМО; 2012. 684 С. [Torshin IYu, Gromova OA. Ekspertnyi analiz dannykh v molekulyarnoi farmakologii [Expert data analysis in molecular pharmacology]. Moscow: MTsNMO; 2012. 684 P.]
23. Громова ОА, Панасенко ОМ, Скальный АВ. Структурный анализ и ферментативная антиокислительная активность нейрометаболических препаратов природного происхождения: церебролизина, церебролизата, билобила и актовегина. Микроэлементы в медицине. 2001;2(1):23-7. [Gromova OA, Panasenko OM, Skal'nyi AV. Structural analysis and fermentative antioxidant activity of neurometabolic preparations of natural origin: Cerebrolysin, Cerebrolysate, bilobil and Actovegin. Mikroelementy v meditsine. 2001;2(1):23-7. (In Russ.)].
24. Громова ОА, Красных ЛВ, Лиманова ОА, Кутузова НА. Коррекция витаминного статуса при синдроме дефицита внимания с гиперактивностью. Российский педиатрический журнал. 2004;(2):53-5. [Gromova OA, Krasnykh LV, Limanova OA, Kutuzova NA. Correction of vitamin status in attention deficit disorder with hyperactivity. Rossiiskii pediatricheskii zhurnal. 2004;(2):53-5. (In Russ.)].
25. Kudrin AV, Gromova OA, Kataev SI. Trace element status of the brain in rats following cerebrolysin administration. J Trace Elem Biol Med. 2004;21(3):3-5.
26. Гаврилова СИ. Фармакотерапия болезни Альцгеймера. Москва: Пульс; 2003. 320 с. [Gavrilova SI. Farmakoterapiya bolezni Al'tsgeimera [Pharmacotherapy of Alzheimer's disease]. Moscow: Pul's; 2003. 320 p.]
27. Gromova OA, Burtsev EM, Avdeenko TV, et al. Cerebrolysin influence on antioxidant and element homeostasis in children with minimal cerebral dysfunction. Trace Elem Electrolyt. 1997;14(3):140-4.
28. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Washington (DC): National Academies Press (US); 1998.
29. Colangelo AM, Bianco MR, Vitagliano L, et al. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J Neurosci. 2008 Mar 12;28(11):2698-709. doi: 10.1523/JNEUROSCI.5201-07.2008.
30. Cline MA, Bowden CN, Calchary WA, Layne JE. Short-term anorexigenic effects of central neuropeptide VF are associated with hypothalamic changes in chicks. J Neuroendocrinol. 2008 Aug;20(8):971-7. doi: 10.1111/j.1365-2826.2008.01749.x. Epub 2008 Jun 6.
31. Yamada N, Katsuura G, Tatsuno I, et al. Orexins increase mRNA expressions of neurotrophin-3 in rat primary cortical neuron cultures. Neurosci Lett. 2009 Jan 30;450(2):132-5. doi: 10.1016/j.neulet.2008.11.028. Epub 2008 Nov 14.
32. Porzionato A, Macchi V, Parenti A, De Caro R. Trophic factors in the carotid body. Int Rev Cell Mol Biol. 2008;269:1-58. doi: 10.1016/S1937-6448(08)01001-0.
33. Suarez V, Guntinas-Lichius O, Streppel M, et al. The axotomy-induced neuropeptides galanin and pituitary adenylate cyclase-activating peptide promote axonal sprouting of primary afferent and cranial motor neurones. Eur J Neurosci. 2006 Sep;24(6):1555-64.
34. Ижбульдина ГИ. Изменения системы гемостаза и свободнорадикального окисления липидов в остром периоде ишемического инсульта на фоне нейропротективной терапии. Журнал неврологии и психиатрии им. C.C. Корсакова. 2012;112(3):31-7. [Izhbul'dina GI. Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on neuroprotection treatment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(3):31-7. (In Russ.)].
35. Chen CC, Wei ST, Tsaia SC, et al. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study. Br J Neurosurg. 2013 Dec;27(6):803-7. doi: 10.3109/02688697.2013.793287. Epub 2013 May 8.
36. Georgy GS, Nassar NN, Mansour HA, Abdallah DM. Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats. PLoS One. 2013;8(6):e64847 Print 2013.
37. Vazquez-Roque RA, Ubhi K, Masliah E, Flores G. Chronic cerebrolysin administration attenuates neuronal abnormalities in the basolateral amygdala induced by neonatal ventral hippocampus lesion in the rat. Synapse. 2014 Jan;68(1):31-8. doi: 10.1002/syn.21718. Epub 2013 Oct 24.
38. Ubhi K, Rockenstein E, Vazquez-Roque R, et al. Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease. Neurosci Res. 2013 Feb;91(2):167-77. doi: 10.1002/jnr.23142. Epub 2012 Nov 14.
39. Alcantara-Gonzalez F, Mendoza-Perez CR, Zaragoza N, Juarez I, Arroyo-Garcia LE, Gamboa C, De La Cruz F, Zamudio S, et al. Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice. Synapse. 2012 Nov;66(11):938-49. doi: 10.1002/syn.21588. Epub 2012 Aug 13.
40. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012 Apr;48 Suppl A:3-24. doi: 10.1358/dot.2012.48(Suppl.A).1739716.
41. Li L, Yu L, Kong Q. Exogenous galanin attenuates spatial memory impairment and decreases hippocampal beta-amyloid levels in rat model of Alzheimer's disease. Int J Neurosci. 2013 Nov;123(11):759-65. doi: 10.3109/00207454. 2013.800976. Epub 2013 Jun 17.
42. Tian L, Guo R, Yue X, et al. Intranasal administration of nerve growth factor ameliorate beta-amyloid deposition after traumatic brain injury in rats. Brain Res. 2012 Feb 27;1440:47-55. doi: 10.1016/j.brainres.2011.12.059. Epub 2012 Jan 8.
43. Onyango IG, Ahn JY, Tuttle JB, et al. Nerve growth factor attenuates oxidant-induced betaamyloid neurotoxicity in sporadic Alzheimer's disease cybrids. J Neurochem. 2010 Sep;114(6):1605-18. doi: 10.1111/j.1471-4159.2010.06871.x. Epub 2010 Jul 30.
44. Yuan J, Huang G, Xiao Z, et al. Overexpression of beta-NGF promotes differentiation of bone marrow mesenchymal stem cells into neurons through regulation of AKT and MAPK pathway. Mol Cell Biochem. 2013 Nov;383(1-2):201-11. doi: 10.1007/s11010-013-1768-6. Epub 2013 Aug 10.
45. Hu YS, Long N, Pigino G, et al. Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3beta, neurotrophin-3 and CREB signaling. PLoS One. 2013 May 21;8(5):e64460. doi: 10.1371/journal.pone.0064460. Print 2013.
46. Diemath HE. Therapeutische Maβnahmen beim akuten Schä dl-Hirn Trauma. Forum für medizinische Fortbildung. Neuhofen; 1992. P. 27-30.
47. Alvarez XA, Sampedro C, Perez P, et al. Cerebrolysin improves brain bioelectrical activity pattern and cognitive functioning in traumatic brain injury and in senile dementia. Int J Neuropharm 2002;5(Suppl 1):S92.
48. Zhang Y, Chopp M, Meng Y, et al. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. J Neurosurg. 2013 Jun;118(6):1343-55. doi: 10.3171/2013.3.JNS122061. Epub 2013 Apr 12.
49. Formichi P, Radi E, Battisti C, et al. Effects of cerebrolysin administration on oxidative stress-induced apoptosis in lymphocytes from CADASIL patients. Neurol Sci. 2013 Apr;34(4):553-6. doi: 10.1007/s10072-012-1174-y. Epub 2012 Aug 10.
50. Kronfeld I, Kazimirsky G, Gelfand EW, Brodie C. NGF rescues human B lymphocytes from anti-IgM induced apoptosis by activation of PKCzeta. Eur J Immunol. 2002 Jan;32(1):136-43.
51. Torcia M, De Chiara G, Nencioni L, et al. Nerve growth factor inhibits apoptosis in memory B lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and cytochrome c release. J Biol Chem. 2001 Oct 19;276(42):39027-36. Epub 2001 Aug 8.
52. Серкина ЕВ, Громова ОА, Торшин ИЮ, Сотникова НЮ. Церебролизин облегчает состояние больных с перинатальными поражениями ЦНС через модуляцию аутоиммунитета и антиоксидантную защиту. Журнал неврологии и психиатрии им. C.C. Корсакова. 2008;108(11):62-6. [Serkina EV, Gromova OA, Torshin IYu, Sotnikova NYu. Cerebrolysin facilitates the condition of patients with perinatal lesions of the Central nervous system through modulation of autoimmunity and antioxidant protection. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(11):62-6. (In Russ.)].
53. Tang CW, Feng WM, Du HM, et al. Delayed administration of D-Ala2-D-Leu5-enkephalin, a delta-opioid receptor agonist, improves survival in a rat model of sepsis. Tohoku J Exp Med. 2011;224(1):69-76.
54. Piva M, Moreno JI, Jenkins FS, et al. In vitro modulation of cytokine expression by enkephalin-derived peptides. Neuroimmunomodulation. 2005;12(6):339-47.
55. Shikata A, Shikata T, Sotozono Y, et al. Neuronal differentiation in human neuroblastoma cells by nerve growth factor following TrkA up-regulation by interferon-gamma. Med Pediatr Oncol. 2000 Jun;34(6):394-401.
56. Calamandrei G, Aloe L, Hajek J, Zappella M. Developmental profile of serum nerve growth factor levels in Rett complex. Ann Ist Super Sanita. 2001;37(4):601-5.
57. Sposato V, Bucci MG, Coassin M, et al. Reduced NGF level and TrkA protein and TrkA gene expression in the optic nerve of rats with experimentally induced glaucoma. Neurosci Lett. 2008 Nov 28;446(1):20-4. doi: 10.1016/j.neulet.2008.09.024. Epub 2008 Sep 18.
58. Громова ОА, Торшин ИЮ, Гоголева ИВ и др. Фармакокинетический и фармакодинамический синергизм между нейропептидами и литием в реализации нейротрофического и нейропротективного действия церебролизина. Журнал неврологии и психиатрии им. С.С. Корсакова, 2015;115(3):65-72. [Gromova OA, Torshin IYu, Gogoleva IV, et al. Pharmacokinetic and pharmacodynamic synergy between neuropeptides and lithium in the implementation of the neurotrophic and neuroprotective action of Cerebrolysin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2015;115(3):65-72. (In Russ.)].
Review
For citations:
Gromova O.A., Pronin A.V., Torshin I.Yu., Kalacheva A.G., Grishina T.R. Neurotrophic and antioxidant potential of neuropeptides and trace elements. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(4):92-100. (In Russ.) https://doi.org/10.14412/2074-2711-2015-4-92-100
Views: 1176
Email this article 